Limited improvement of systemic therapy has been achieved in first line treatment for advanced Biliary tract cancer (BTC). In this randomized phase 2 trial on BTC, the combination of sintilimab, anlotinib, and gemcitabine/cisplatin demonstrated an improvement in progression - free survival (PFS) and objective response rate (ORR) while reducing the risk of disease progression compared to chemotherapy monotherapy.
- Jingjing Li
- Shurui Zhou
- Jieer Ying